Vaccine最新文献

{"title":"Raman spectroscopy as a tool for detection of lung cancer and verification of vaccination effect – Correlation with biochemical data","authors":"Jolanta Smok-Kalwat ,&nbsp;Stanisław Góźdź ,&nbsp;Paweł Macek ,&nbsp;Zuzanna Kalwat ,&nbsp;Magdalena Sawic ,&nbsp;Anna Sroka-Bartnicka ,&nbsp;Andrzej Stepulak ,&nbsp;Joanna Depciuch","doi":"10.1016/j.vaccine.2024.126690","DOIUrl":"10.1016/j.vaccine.2024.126690","url":null,"abstract":"<div><div>Pneumonia and other comorbidities can reduce the efficacy of chemotherapy and other treatment modalities in lung cancer. The risk of these diseases can be lower after vaccination. Therefore, in this study, an investigation of the 13-valent pneumococcal conjugate vaccine (PCV13) on the immune system of lung cancer patients (study group) and individuals without cancer symptoms (control group) was performed. Raman spectroscopy was used to measure and analyze biochemical changes in serum spectra collected from 116 lung cancer patients and 19 healthy individuals as a control samples before and after PCV13 vaccine. Obtained results showed that in study groups, both the post-vaccination and control groups exhibited increased IgG and IgG2 levels. Raman spectra revealed that vaccination caused a shift of peaks towards higher Raman shifts in both groups, however, this shift was pronounced in the study group. Using Raman spectroscopy, it was possible to differentiate not only patients with and without lung cancer, but also patients before and after vaccination. The area under Receiver Operating Characteristic (AUC-ROC) ranged from 0.794 when comparing study and control groups post-vaccination to 0.575 when comparing control patients pre- and post-vaccination. Correlations between biochemical parameters (IgG, IgG2, monocytes, and C-reactive protein (CRP)) and Raman data differed in the study group, while in the control one correlation remained consistent. This study shows the potential of Raman spectroscopy for detecting lung cancer from serum as well as for verifying the impact of the PCV13 vaccine on the chemical compositions of serum and the immune system.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126690"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143176913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines","authors":"Jeong-Yeon Cho ,&nbsp;Haeseon Lee ,&nbsp;Warisa Wannaadisai ,&nbsp;Jeffrey Vietri ,&nbsp;Nathorn Chaiyakunapruk","doi":"10.1016/j.vaccine.2024.126656","DOIUrl":"10.1016/j.vaccine.2024.126656","url":null,"abstract":"<div><h3>Background</h3><div>The economic and public health benefits of adult pneumococcal vaccines vary across countries due to different epidemiology and costs. We systematically reviewed and summarized findings and assumptions of cost-effectiveness analyses (CEA) of the recently introduced 15- and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) in adults.</div></div><div><h3>Methods</h3><div>We performed a systematic search for CEA studies of PCV15 and/or PCV20 versus existing strategies via PubMed, EMBASE, CEA Registry, EconLit, HTA Database, and NITAG resource center through April 23, 2024. Study characteristics, methods, assumptions, and findings were extracted independently by two reviewers; quality was assessed using ECOBIAS. Results were synthesized qualitatively to summarize key attributes and conclusions.</div></div><div><h3>Results</h3><div>Of 137 identified records, 26 studies were included; the majority (24/26) concerned high-income countries. All employed static Markov-type models comparing higher-valent PCVs used alone or in combination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) to current recommendations (PPSV23 alone, PCV13 alone, PCV13 + PPSV23, no vaccination). Most studies (22/26) concluded PCV20 used alone was cost-saving (dominant) or cost-effective compared to other adult pneumococcal strategies (PPSV23 alone, PCV13 ± PPSV23, PCV15 ± PPSV23, or no vaccination). PCVs were generally assumed to have serotype-specific effectiveness equal to PCV13 efficacy in the pivotal trial, though four studies used estimates from a Delphi panel; protection was assumed to last between 10 and 20 years. PPSV23 was assumed to have lower effectiveness against non-bacteremic pneumonia and shorter duration of protection. Herd effects from higher-valent PCVs in childhood (12/26), serotype replacement (2/26), or both (1/26) were included in half (13/26) of studies, which attenuated adult vaccine impact. Most studies were assessed as low risk of bias; five abstracts did not provide sufficient information for assessment.</div></div><div><h3>Conclusion</h3><div>Current evidence indicates that 20-valent PCV used alone is likely to be cost-effective or dominate other adult pneumococcal strategies. Future research is needed to address remaining uncertainties in assumptions and to support evidence-based policymaking.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126656"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines","authors":"Esmeralda Alvarado-Facundo ,&nbsp;Rachel Herrup ,&nbsp;Wei Wang ,&nbsp;Rhonda E. Colombo ,&nbsp;Limone Collins ,&nbsp;Anuradha Ganesan ,&nbsp;David Hrncir ,&nbsp;Tahaniyat Lalani ,&nbsp;Ana Elizabeth Markelz ,&nbsp;Ryan C. Maves ,&nbsp;Bruce McClenathan ,&nbsp;Katrin Mende ,&nbsp;Stephanie A. Richard ,&nbsp;Kat Schmidt ,&nbsp;Christina Schofield ,&nbsp;Srihari Seshadri ,&nbsp;Christina Spooner ,&nbsp;Christian L. Coles ,&nbsp;Timothy H. Burgess ,&nbsp;Carol D. Weiss ,&nbsp;Maryna Eichelberger","doi":"10.1016/j.vaccine.2024.126669","DOIUrl":"10.1016/j.vaccine.2024.126669","url":null,"abstract":"<div><div>Neuraminidase (NA)-specific antibodies contribute to immunity against influenza. While studies have demonstrated increased NA inhibiting (NAI) antibody titers after vaccination with egg-derived inactivated influenza vaccines (eIIV), the response to cell culture-derived (c) IIV has not been reported.</div></div><div><h3>Methods</h3><div>An immunogenicity sub-study was performed within a clinical trial comparing the effectiveness of egg, cell, and recombinant hemagglutinin (HA)-derived influenza vaccines during the 2018–2019 and 2019–2020 influenza seasons. NAI and neutralizing antibody titers against the A(H1N1)pdm09 and A(H3N2) components of the vaccines were measured in pre- and post-vaccination sera.</div></div><div><h3>Results</h3><div>Responses to the N1 component of eIIV and cIIV were different in both study years 1 and 2 whereas response rate and antibody titers to the N2 component of egg and cell culture-derived vaccines were similar. For example, 43.5 % of eIIV and no cIIV recipients had four-fold NAI titer increases in year 1. There was a weak positive correlation between responses to N1 and N2 for both vaccine types but no correlation between NAI and HA-specific neutralizing antibody responses. Recombinant HA vaccine that does not contain NA served as a specificity control; NAI antibody titers did not increase in recipients except in two individuals presumed to have subclinical infection.</div></div><div><h3>Conclusion</h3><div>Antibody responses to NA following vaccination with eIIV and cIIV were not the same; although the responses to the N1 and N2 components of eIIV were similar, there were fewer responders to N1 than N2 of cIIV. Studies to determine the impact of NA immunity on influenza vaccine effectiveness are warranted.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126669"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine","authors":"Bryan S. Kaplan ,&nbsp;Carine K. Souza ,&nbsp;J. Brian Kimble ,&nbsp;Meghan Wymore Brand ,&nbsp;Tavis K. Anderson ,&nbsp;Phillip C. Gauger ,&nbsp;Daniel R. Perez ,&nbsp;Amy L. Baker","doi":"10.1016/j.vaccine.2024.126574","DOIUrl":"10.1016/j.vaccine.2024.126574","url":null,"abstract":"<div><div>Influenza A viruses (IAV) of subtypes H1N1, H1N2, and H3N2 are endemic in US domestic swine populations and contribute to significant economic losses annually and pose a persistent pandemic threat. Adjuvanted, whole-inactivated virus (WIV) vaccines are the primary countermeasure to control IAV in swine. The compositions of these vaccines are matched for hemagglutinin (HA) strain and content, often ignoring the other IAV glycoprotein, the neuraminidase (NA). The IAV NA is immunogenic and antibodies targeting epitopes adjacent to the active site have been shown to inhibit the sialidase activity of NA thereby reducing virus replication and shedding. To assess the ability of neuraminidase inhibiting (NAI) antibodies induced from WIV administration to protect swine from challenge with IAV containing homologous and heterologous NA, we produced WIV composed of viruses with an irrelevant mismatched H9 HA but expressing NA proteins from two predominant clades (N2–2002A.2 and N2<img>2002B.2) currently circulating in US domestic swine populations. Pigs that received two doses of H9N2 WIV developed vaccine-specific neuraminidase inhibition antibodies and when challenged with a wild-type H3N2 virus containing homologous NA, displayed reduced virus shedding in the upper respiratory tract and decreased virus titers in the lung compared to unvaccinated controls. Pigs challenged with H3N2 containing a heterologous NA also had reduced virus titers in the nasal swab and BALF samples. Together these results show that NAI antibodies cross-protected across phylogenetic clades and reduced virus replication and shedding in swine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126574"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice","authors":"Yao Ma ,&nbsp;Chunhong Dong ,&nbsp;Joo Kyung Kim ,&nbsp;Wandi Zhu,&nbsp;Lai Wei,&nbsp;Ye Wang,&nbsp;Sang-Moo Kang,&nbsp;Bao-Zhong Wang","doi":"10.1016/j.vaccine.2024.126670","DOIUrl":"10.1016/j.vaccine.2024.126670","url":null,"abstract":"<div><div>The immune memory imprinted during an individual's initial influenza exposure (influenza imprinting) has long-lasting effects on the host's response to subsequent influenza infections and vaccinations. Here, we investigate how different influenza virus imprinting impacts the immune responses to subunit, inactivated virus, and protein-based nanoparticle vaccines in Balb/c mice. Our results indicated a phylogenetic distance-dependent effect of influenza imprinting on subunit hemagglutinin (HA) or formalin-inactivated (FI) virus vaccine immunizations. Aichi (H3N2, group 2) HA (HA3) or FI-Aichi vaccination in mice imprinted with closely related Phili (H3N2) triggered significant Aichi-specific HAI antibody and balanced HA3-specific Th1/Th2 antibody immune responses, resulting in robust protection against Aichi. In contrast, HA3 vaccination in PR8 (H1N1, group 1) imprinted mice (PR8-2HA3) induced Th2-leaning responses comparable to those observed in mice without prior influenza immune imprinting (PBS-2HA3). However, subsequent heterosubtypic infections and vaccinations eliminated such effects on antibody subtype profiles. Nonetheless, initial virus exposure established a long-lasting capacity to produce HAI antibody responses against the imprinting strains. Moreover, Phili imprinting followed by HA3/NP nanocluster vaccination protected mice from Aichi infections and induced enhanced cross-reactive immunity. Our study highlights the significance of considering an individual's influenza exposure history when designing and evaluating the effectiveness of influenza vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126670"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season","authors":"Jiaojiao Zhang ,&nbsp;Li Zhang ,&nbsp;Jia Li ,&nbsp;Jiaoxin Ma ,&nbsp;Yingying Wang ,&nbsp;Ying Sun ,&nbsp;Chunna Ma ,&nbsp;Wei Duan ,&nbsp;Quanyi Wang ,&nbsp;Peng Yang ,&nbsp;Daitao Zhang","doi":"10.1016/j.vaccine.2024.126662","DOIUrl":"10.1016/j.vaccine.2024.126662","url":null,"abstract":"<div><h3>Introduction</h3><div>The objective of our study was to estimate the influenza vaccine effectiveness for 2023/24 epidemic of co-circulating influenza A(H3N2) and B(Victoria) viruses in Beijing, China.</div></div><div><h3>Methods</h3><div>The surveillance-based study included all swabbed patients through influenza virological surveillance in Beijing, between October 2023 and March 2024. A Test-Negative Design(TND) was used to estimate influenza vaccine effectiveness(VE) against medically- attended laboratory-confirmed influenza in outpatient settings, also calculated the influenza vaccination rate(IVR). Cases were influenza-like illness (ILI) patients who tested positive for influenza, and controls were ILI who influenza negative patients.</div></div><div><h3>Results</h3><div>A total of 18,665 ILI patients were enrolled and swabbed. Among them, 6362(34.1 %) tested positive for influenza, major epidemic strain was A(H3N2) and B(Victoria). The overall IVR was 8.7 %, and the differences of IVR by gender, age, region, chronic conditions and month of onset were statistically significant(P&lt;0.05). The adjusted VE against all influenza was moderate at 44.8 %, with the highest for B (Victoria) at 52.2 %, the highest for 19–59 age at 72.4 %, and the highest when vaccinated only in current season at 48.3 %.</div></div><div><h3>Conclusion</h3><div>Our study suggested the influenza vaccine has moderate effectiveness, with the best VE against B(Victoria), followed by A(H3N2) and A(H1N1)pdm09 in Beijing, 2023/24 season. Meanwhile, the influenza VE was relatively high in school-age children and the elderly. Consistent long-term studies are required in the future to evaluate the protect effect of influenza vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126662"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustainability of measles, rubella, and congenital rubella syndrome (CRS) elimination in the United States, January 2022 – June 20241","authors":"Alan R. Hinman,&nbsp;Emily Banerjee,&nbsp;Noel T. Brewer,&nbsp;Elisabeth S. Hayes,&nbsp;David Kimberlin,&nbsp;Walter A. Orenstein,&nbsp;Michele Roberts,&nbsp;Jane R. Zucker","doi":"10.1016/j.vaccine.2024.126681","DOIUrl":"10.1016/j.vaccine.2024.126681","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126681"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142916759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry","authors":"Anna Dermenchyan ,&nbsp;Kristen R. Choi ,&nbsp;Pooya R. Bokhoor ,&nbsp;David J. Cho ,&nbsp;Nina Lou A. Delavin ,&nbsp;Chidinma Chima-Melton ,&nbsp;Maria A. Han ,&nbsp;Gregg C. Fonarow","doi":"10.1016/j.vaccine.2024.126682","DOIUrl":"10.1016/j.vaccine.2024.126682","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure affects people of all ages and is a leading cause of death for both men and women in most racial and ethnic groups in the United States. Infections are common causes of hospitalizations in heart failure, with respiratory infections as the most frequent diagnosis. Vaccinations provide significant protection against preventable respiratory infections. Despite being an easily accessible intervention, prior studies suggest vaccines are underused in patients with heart failure.</div></div><div><h3>Methods</h3><div>An observational study of 5089 adults with heart failure was conducted using data from an integrated, multicenter, academic health system in Southern California from 2019 to 2022. Logistic regression models were used to determine the rates of influenza, pneumococcal, and COVID-19 vaccination among a population of patients with heart failure (heart failure preserved ejection fraction [HFpEF], heart failure mildly reduced ejection fraction [HFmrEF], and heart failure reduced ejection fraction [HFrEF], and identify whether heart failure phenotype is associated with vaccination status.</div></div><div><h3>Results</h3><div>Vaccination rates varied between influenza, pneumococcal, and COVID-19 vaccines. Of the three respiratory vaccines, 58.0 % of patients had received an influenza vaccine, 76.2 % had received a pneumococcal vaccine, and 83.3 % had received a COVID-19 vaccine. There were no sex-based differences by vaccination status. Differences were seen within age, race/ethnicity, insurance type, whether the patient was a member of an Accountable Care Organization (ACO), primary language, Social Vulnerability Index (SVI) score, clinician type, and number of comorbidities. Patients with HFpEF and HFmrEF had higher vaccination rates than HFrEF. In adjusted models, patients with HFrEF had lower odds of being vaccinated for influenza (aOR = 0.75, 95 % CI = 0.66–0.86), pneumococcal (aOR = 0.65, 95 % CI = 0.55–0.75), and COVID (aOR = 0.74, 95 % CI = 0.62–0.89) compared to patients with HFpEF.</div></div><div><h3>Conclusions</h3><div>Patients with HFrEF had the lowest levels of respiratory vaccination compared to other specified heart failure categories. Interventions are needed to increase vaccination education and offerings, especially to patients with HFrEF.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126682"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.","authors":"Moin S Vahora ,&nbsp;Otávio Leão ,&nbsp;Mariângela Freitas da Silveira ,&nbsp;Marlos Rodrigues Domingues ,&nbsp;Pedro C Hallal ,&nbsp;Alicia N.M. Kraay","doi":"10.1016/j.vaccine.2025.126838","DOIUrl":"10.1016/j.vaccine.2025.126838","url":null,"abstract":"<div><div>In this study, we examine the association between COVID-19 vaccination and antibody titer and whether this association varies by nutritional status and duration of school attendance using linear regression models applied to seven-year-old children from the 2015 Pelotas (Brazil) Birth Cohort (<em>n</em> = 2956). Antibody titers were 0.29 optical density (OD) titer units higher among vaccinated compared with unvaccinated children (95 % CI: 0.24, 0.34). Duration of school enrollment was associated with increased antibody titer, with each month being associated with a 0.15 unit increase in OD titer (95 % CI: 0.14, 0.16). Stunting was associated with lower COVID-19 titers among unvaccinated children (−0.10, 95 % CI: −0.21,0.004), but not among vaccinated children. Stunted children may have poorer immune responses to natural infection, but vaccination can overcome this deficit. Population-wide follow-up vaccination may be beneficial, particularly prior to school entry and for stunted children to reduce the risk of natural infection.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"49 ","pages":"Article 126838"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143334871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles","authors":"Devaki Pilapitiya ,&nbsp;Wen Shi Lee ,&nbsp;Mai N. Vu ,&nbsp;Andrew Kelly ,&nbsp;Rosela H. Webster ,&nbsp;Marios Koutsakos ,&nbsp;Stephen J. Kent ,&nbsp;Jennifer A. Juno ,&nbsp;Hyon-Xhi Tan ,&nbsp;Adam K. Wheatley","doi":"10.1016/j.vaccine.2024.126668","DOIUrl":"10.1016/j.vaccine.2024.126668","url":null,"abstract":"<div><div>Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal and systemic responses. Using reverse genetics, we generated replication-competent recombinant influenza viruses carrying heterologous RBD genes in monomeric, trimeric, or ferritin-based nanoparticle forms. Following intranasal immunisation, mice developed potent serological anti-RBD responses, with ferritin nanoparticles superseding monomeric or trimeric RBD responses. While parenteral and mucosal immunisation elicited robust anti-RBD IgG in serum, mucosal immunisation seeded respiratory IgA, RBD-specific lung-resident memory and germinal centre (GC) B cells. In animals with prior intramuscular vaccination, intranasal boosting with recombinant influenza vectors augmented mucosal IgG, IgA, GC and memory B cells, and SARS-CoV-2 lung neutralising titres. Recall of RBD-specific memory B cells via antigen re-exposure in the lung increased antibody-secreting cells in the lung-draining lymph nodes, with maintenance of lung GC B cells. Recombinant influenza-based vaccines effectively deliver highly immunogenic self-assembling nanoparticles, generating antibodies and B cells in the respiratory mucosa. This strategy provides a tractable pathway to augment lung-localised responses against recurrent respiratory viral infections.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"46 ","pages":"Article 126668"},"PeriodicalIF":4.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}